Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KLK7 | P49862 | 1/20 | 0.53 |
| ▸ | KLK5 | Q9Y337 | 1/20 | 0.53 |
| ▸ | MAOA | P21397 | 5/20 | 0.48 |
| ▸ | MAOB | P27338 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.47 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.46 |
| ▸ | KIT | P10721 | 6/20 | 0.45 |
| ▸ | PDGFRA | P16234 | 6/20 | 0.45 |
| ▸ | KDR | P35968 | 6/20 | 0.45 |
| ▸ | FLT4 | P35916 | 4/20 | 0.45 |
| ▸ | FLT3 | P36888 | 4/20 | 0.45 |
| ▸ | PDGFRB | P09619 | 2/20 | 0.42 |
| ▸ | MAP2K1 | Q02750 | 2/20 | 0.42 |
| ▸ | ACVRL1 | P37023 | 2/20 | 0.42 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.42 |
| ▸ | MAP2K2 | P36507 | 1/20 | 0.42 |
| ▸ | FLT1 | P17948 | 1/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL846317 | 0.85 | KLK7 (0.73) | KLK7KLK5MAOAMAOBKDM4E | |
| SCHEMBL3366271 | 0.80 | OPRD1 (0.62) | KLK7KLK5MAOAMAOBKDM4E | |
| SCHEMBL2314134 | 0.80 | OPRD1 (0.62) | KLK7KLK5MAOAMAOBKDM4E | |
| SCHEMBL638027 | 0.76 | MAOA (0.64) | KLK7KLK5MAOAMAOBKDM4E | |
| SCHEMBL13925624 | 0.75 | KLK7 (0.67) | KLK7KLK5MAOAMAOBKDM4E | |
| SCHEMBL3366320 | 0.74 | MEN1 (0.64) | KLK7KLK5MAOAMAOBKDM4E | |
| SCHEMBL13925623 | 0.72 | ACHE (0.61) | KLK7KLK5MAOAMAOBPOLB | |
| SCHEMBL31371856 | 0.72 | KLK7 (0.73) | KLK7KLK5MAOAMAOBKDM4E | |
| SCHEMBL29009458 | 0.72 | KLK7 (0.73) | KLK7KLK5MAOAMAOBKDM4E | |
| SCHEMBL29885475 | 0.71 | MAOA (0.57) | KLK7KLK5MAOAMAOBKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 83 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026043908-A1 | COMPOSITIONS AND METHODS TO IMPROVE SEQUESTRATION OF MYCOTOXINS AND THEIR USE IN DETOXIFICATION OF ANIMAL FEED AND ANIMAL PRODUCTION SYSTEMS | ALLTECH, INC. (US) | 2026-02-26 | — | — | WO | claimed |
| EP-3771487-A1 | METHOD FOR THE SIMULTANEOUS DETERMINATION OF VARIOUS ANALYTES IN AN ENVIRONMENTAL SAMPLE AND / OR AN AGRICULTURAL RAW MATERIAL BASED ON CORE-SHELL MICROPARTICLES | Bundesrepublik Deutschland, Vertreten durch den Bundesminister für Wirtschaft und Energie, dieser Vertreten durch den Präsidenten der (DE) | 2021-02-03 | — | — | EP | claimed |
| EP-0448392-A2 | Xanthomegnin, a known compound, is an antiparasitic agent | MERCK & CO. INC. (US) | 1991-09-25 | — | — | EP | claimed |
| US-5017603-A | Xanthomegnin, a known compound, is an antiparasitic agent | MERCK & CO., INC. (US) | 1991-05-21 | — | — | US | claimed |
| JP-4217677-A | — | — | None | — | — | JP | disclosed |
| JP-4217677-A | — | — | None | — | — | JP | disclosed |
| EP-2841109-B1 | PRODRUGS OF HYDROXYL-COMPRISING DRUGS | ASCENDIS PHARMA AS (DK) | 2026-04-15 | — | — | EP | disclosed |
| WO-2026043908-A1 | COMPOSITIONS AND METHODS TO IMPROVE SEQUESTRATION OF MYCOTOXINS AND THEIR USE IN DETOXIFICATION OF ANIMAL FEED AND ANIMAL PRODUCTION SYSTEMS | ALLTECH, INC. (US) | 2026-02-26 | — | — | WO | disclosed |
| US-20250360073-A1 | SOLUBILIZING PIGMENTS EXTRACTED FROM FUNGI FOR APPLICATIONS SUCH AS COSMETIC PRODUCTS | ADLER JESSE (US) | 2025-11-27 | — | — | US | disclosed |
| EP-3782649-B1 | BIODEGRADABLE POLYETHYLENE GLYCOL BASED WATER-INSOLUBLE HYDROGELS | ASCENDIS PHARMA AS (DK) | 2025-05-14 | — | — | EP | disclosed |
| WO-2025059358-A1 | FUNGAL STRAINS HAVING REDUCED OR ELIMINATED MYCOTOXIN, ETHANOL, AND/OR PIGMENT PRODUCTION CAPACITY | THE FYNDER GROUP, INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| US-20230381323-A1 | RELEASABLE CONJUGATES | FISH & RICHARDSON PC | 2023-11-30 | — | — | US | disclosed |
| EP-0448392-A2 | Xanthomegnin, a known compound, is an antiparasitic agent | MERCK & CO. INC. (US) | 1991-09-25 | — | — | EP | disclosed |
| US-5017603-A | Xanthomegnin, a known compound, is an antiparasitic agent | MERCK & CO., INC. (US) | 1991-05-21 | — | — | US | disclosed |
| US-5017603-A | Xanthomegnin, a known compound, is an antiparasitic agent | MERCK & CO., INC. (US) | 1991-05-21 | — | — | US | disclosed |
| US-5017603-A | Xanthomegnin, a known compound, is an antiparasitic agent | MERCK & CO., INC. (US) | 1991-05-21 | — | — | US | disclosed |
| US-4963581-A | PREVENTION OR TREATMENT OF BREAST CANCER; INHIBITOR OF AROMATASE, LOWERING ESTROGEN LEVEL | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 1990-10-16 | — | — | US | disclosed |
| EP-0337413-A2 | Naphthopyran derivatives and use thereof | Takeda Chemical Industries, Ltd. (JP) | 1989-10-18 | — | — | EP | disclosed |
| EP-0334421-A1 | Antifungal fermentation product and derivatives and compositions thereof | MERCK & CO. INC. (US) | 1989-09-27 | — | — | EP | disclosed |
| US-4847284-A | PYRROLIDINOL ANTIBIOTICS | MERCK & CO., INC. (US) | 1989-07-11 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230381323-A1 | RELEASABLE CONJUGATES | GUSB, ABCB11, UGT2B7 | KLK7 2010/4885KLK5 2360/4885MAOA 164/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.